---
title: "Grifols Doses First Patients in Two Phase 3 Trials to Expand Indications of its Flagship Immunoglobulins"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/292904153.md"
description: "Grifols has initiated dosing for the first patients in two Phase 3 trials aimed at expanding U.S. market approval for its flagship immunoglobulin therapies, GAMUNEX-C and XEMBIFY. The global healthcare company, listed on NASDAQ under GRFS, seeks to broaden indications for these plasma-derived medicines."
datetime: "2026-07-16T12:00:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/292904153.md)
  - [en](https://longbridge.com/en/news/292904153.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/292904153.md)
generator: "portal-rs"
---

# Grifols Doses First Patients in Two Phase 3 Trials to Expand Indications of its Flagship Immunoglobulins

In Barcelona, Spain, on July 16, 2026, a major global healthcare company, Grifols, disclosed that they have begun dosing the initial patients in two distinct Phase 3 trials. The objective of these trials is to broaden the U.S. market approval for their key immunoglobulin medications. These include GAMUNEX ® -C, an intravenous immunoglobulin (IVIg), and XEMBIFY ®, a subcutaneous immunoglobulin (SCIg). Grifols is recognized as a top producer of plasma-derived medicines and is listed on the MCE under tickers GRF and GRF.P, as well as on the NASDAQ under ticker GRFS.

### Related Stocks

- [GRFS.US](https://longbridge.com/en/quote/GRFS.US.md)

## Related News & Research

- [Jensen Huang: Nvidia’s Vera Rubin Platform Turns Electricity Into a $40 Billion Cash Machine](https://longbridge.com/en/news/297688917.md)
- [Essential Utilities (WTRG) Could Be 20% Undervalued After Customer Growth And Investment Plans](https://longbridge.com/en/news/297760750.md)
- [Short Interest in A.P. Moller-Maersk (OTCMKTS:AMKBY) Declines By 46.8%](https://longbridge.com/en/news/297415327.md)
- [Algoma Steel resumes EAF output under interim power plan after Lake Superior outage](https://longbridge.com/en/news/297777897.md)
- [Viasat’s Inmarsat links GMDSS distress calls, weather alerts in new maritime risk analysis](https://longbridge.com/en/news/297612053.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**